Literature DB >> 10519404

Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies.

S M Di Stasi1, A Giannantoni, R Massoud, S Dolci, P Navarra, G Vespasiani, R L Stephen.   

Abstract

The objectives of these investigations were: (a) to make a preliminary study to assess concentration-depth profiles of mitomycin C (MMC) in the bladder wall at specified time intervals after passive diffusion (PD); and (b) to conduct a major study to compare concentration-depth profiles after PD and electromotive drug administration (EMDA) of MMC. Full thickness sections of viable human bladder wall were placed in two-chamber cells with urothelium exposed to donor compartments containing 40 mg of MMC in 100 ml of 0.96% NaCl solutions and with serosa-facing receptor compartments containing 0.9% NaCl solutions. In the preliminary study during each of nine experimental sessions, five sections of bladder wall were individually exposed to MMC for either 5, 15, 30, 45, or 60 min. In the major study, an anode and a cathode were sited in the donor and receptor compartments, and 14 paired experiments--current (20 mA)/no current--were conducted over a 30-min period. Bladder wall sections were cut serially into 40-microm slices parallel to the urothelium and analyzed by high-performance liquid chromatography for MMC concentration (microg/g wet tissue weight). Tissue viability and morphology and MMC stability were assessed by trypan-blue exclusion test, histological examination, and mass spectrometry analysis. In the preliminary study (PD only), mean MMC concentrations (microg) at 5, 15, 30, 45, and 60 min were: (a) for urothelium, 15.3, 60.0, 58.2, 60.1, and 57.8, respectively; (b) for lamina propria, 2.2, 18.9, 19.3, 16.1, and 17.3, respectively; and (c) for muscularis, 0.4, 2.0, 1.8, 1.3, and 2.4, respectively. In the comparative study, MMC concentrations and coefficients of variation (CV) were as follows: (a) for urothelium after PD, 46.6 with CV = 69%, and after EMDA, 170.0 with CV = 43% (P < 0.0001); (b) for lamina propria after PD, 16.1, with CV = 60%, and after EMDA, 65.6 with CV = 29% (P < 0.0001); and (c) for muscularis after PD, 1.9 with CV = 82%, and after EMDA, 15.9 with CV = 82% (P < 0.0005). All of the bladder sections remained viable, and the chemical structure of MMC was unchanged. It was concluded that EMDA significantly enhances MMC transport into all of the layers of the bladder wall, and sections of viable human bladder are a reliable tool for assessing different modes of drug delivery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519404

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.

Authors:  Yuval Freifeld; Yoram Dekel; Avi Stein
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

2.  [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].

Authors:  C Rehme; C Niedworok; H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

Review 3.  Alternative therapies in patients with non-muscle invasive bladder cancer.

Authors:  Öner Şanlı; Yair Lotan
Journal:  Turk J Urol       Date:  2017-12-01

Review 4.  Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Jonathan Aning; Joseph Ischia; Alan So; Peter Black
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 5.  Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder.

Authors:  Savino M Di Stasi; Francesco De Carlo; Vincenzo Pagliarulo; Francesco Masedu; Cristian Verri; Francesco Celestino; Claus Riedl
Journal:  Ther Adv Urol       Date:  2015-12

6.  Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.

Authors:  Savino Mauro Di Stasi; Claus Riedl
Journal:  World J Urol       Date:  2009-02-21       Impact factor: 4.226

7.  The stability of lidocaine and epinephrine solutions exposed to electric current and comparative administration rates of the two drugs into pig bladder wall.

Authors:  Savino M Di Stasi; Antonella Giannantoni; Pierluigi Navarra; Renato Massoud; Daniela Zavaglia; Pierfrancesco Bertucci; Giuseppe Vespasiani; Robert L Stephen
Journal:  Urol Res       Date:  2003-05-08

Review 8.  Intravesical treatments of bladder cancer: review.

Authors:  Zancong Shen; Tong Shen; M Guillaume Wientjes; Michael A O'Donnell; Jessie L-S Au
Journal:  Pharm Res       Date:  2008-03-28       Impact factor: 4.200

Review 9.  Intravesical electromotive drug administration for non-muscle invasive bladder cancer.

Authors:  Jae Hung Jung; Ahmet Gudeloglu; Halil Kiziloz; Gretchen M Kuntz; Alea Miller; Badrinath R Konety; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-09-12

Review 10.  [Intravesical therapy in non-muscle-invasive bladder cancer: indications and practical considerations].

Authors:  J Simon; F Finter; T Schnöller; R Hautmann; L Rinnab
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.